Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Editors for the journal and the Section Editors for this issue.
David A. Cooper
David A. Cooper AO FAA is Scientia Professor of Medicine and Director of the Kirby Institute at the University of New South Wales, Sydney, Australia. The Kirby Institute is funded by the Commonwealth Department of Health and Ageing to conduct research into blood-borne viruses including HIV and viral hepatitis in Australia with the ultimate aim of reducing the burden of disease for the affected communities.
The major responsibilities of the Kirby Institute are the epidemiology and surveillance of blood-borne viruses in Australia, including research aspects and the coordination and conduct of clinical trials of innovative therapies and vaccines for HIV and viral hepatitis, as well as an active clinical research program with particular emphasis on HIV infection, viral hepatitis and sexually-transmitted infections.
In addition to the Kirby Institute, Professor Cooper is a physician in the Immunology/HIV/Infectious Diseases Clinical Services Unit at St Vincent's Hospital, Sydney, Australia, one of the largest inpatient and outpatient services for the treatment of HIV disease in Australia. He is also Director of the St Vincent's Hospital Centre for Applied Medical Research. Professor Cooper is an author on over 750 published scientific papers and is on the editorial boards of several international journals.
Internationally, Professor Cooper is recognized as a leading HIV clinician and clinical investigator. He is a past President of the International AIDS Society. He is a Director of HIVNAT, a clinical research and trials collaboration based at the Thai Red Cross AIDS Research Centre at the Chulalongkorn University Hospital in Bangkok, Thailand. He is actively involved in strategic studies of antiretroviral therapy for HIV infection in the developed and developing world as well as studies of HIV vaccines and chemoprophylaxis.
Professor Giuseppe Pantaleo was born June 17, 1956 in Bari, Italy. In 1980, he received his degree in medicine with full marks and honors, and in 1983, he became board certified in clinical hematology.
His scientific career in the field of immunology began in 1983 working on the development of a limiting dilution cloning system which was critical for the subsequent studies aimed at the phenotypic and functional characterization of circulating T lymphocytes. From 1985 to 1987 he was amongst the pioneers in the delineation of the molecular and biochemical mechanisms involved in signal transduction in human T lymphocytes.
In 1989, Professor Pantaleo joined the Laboratory of Immunoregulation, NIAID, NIH. He was the first to demonstrate the defective clonogenic potential of CD8+ T lymphocytes and the selective defect of HIV-specific cytotoxic T lymphocytes. He then studied the relationship between immune response and viral reservoirs in different anatomic compartments. He demonstrated that lymphoid organs function as a major reservoir for HIV, and that active virus replication occurs in lymphoid organs throughout the course of HIV disease including the prolonged period of clinical latency. These findings have completely changed the clinical and therapeutic management of HIV infection. In the following years, Professor Pantaleo has continued to provide important contributions to the understanding the immunopathogenesis of HIV infection. Amongst these it is noteworthy to mention the delineation of the virologic and immunologic events associated with primary HIV infection, and the observation that the proportion of CD8+ T cells involved in antiviral immune response was substantially higher compared to what was previously estimated.
Since 1997 he has pioneered the field of immune-based intervention in HIV infection and he has been part of a European program for the development of a vaccine against HIV-AIDS. Since 2005, he has led the Poxvirus T-cell Vaccine Discovery Consortium, an international program to develop an HIV vaccine, supported by the Bill and Melinda Gates Foundation.
Professor Pantaleo is author and co-author of about 250 publications in international scientific journals, he is on the editorial boards of several international journals and serves as ad hoc reviewer for several international journals.
Professor Pantaleo is Professor of Medicine and Chief of the Division of Immunology and Allergy (IAL) and of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. Since 2007, he has also been Executive Director of the Swiss Vaccine Research Institute. Since 2009, he has been a member of the WHO Vaccine Program scientific committee and a member of the science committee of the Global HIV Vaccine Enterprise.
Joep Lange is Professor of Medicine at the Academic Medical Center (AMC), University of Amsterdam, the Netherlands, where he heads the Department of Global Health and the Amsterdam Institute for Global Health and Development (AIGHD).
Dr Lange has been involved in HIV research and treatment since 1983. In addition to various positions at the AMC, he was Chief of Clinical Research and Drug Development at the Global Programme on AIDS of the World Health Organization in Geneva, Switzerland, from 1992 to 1995. From 2002 to 2004 he was President of the International AIDS Society. He has been the architect and principal investigator of several pivotal trials on antiretroviral therapy and prevention of mother-to-child transmission in both the developed and developing world. He has also been one of the leading actors in increasing access to HIV treatment in resource-poor settings.
Dr Lange serves as the Chairman of the Supervisory Board of PharmAccess Foundation (which he founded) and as Scientific Advisor to the Board of the Health Insurance Fund Foundation, which pioneers mechanisms of sustainable financing of health care in resource-poor settings. He is co-founder and co-director of the HIV Netherlands Australia Thailand Research Collaboration (HIVNAT), based in Bangkok, Thailand; is a member of the Supervisory Board of the KNCV Tuberculosis Foundation; and, a member of the Board of the Council for Health Service Accreditation of Southern Africa (COHSASA).
In addition, Dr Lange serves on numerous advisory boards for both private and public sector organizations. He is Editor-in-Chief of Antiviral Therapy, author or co-author of over 350 papers in peer-reviewed scientific journals and book chapters, and has guided more than 40 PhD students. In 2007 he was awarded the Eijkman medal for his achievements in Tropical Medicine and International Health. In 2008, he was co-author of a prize-winning provocative essay of the International Finance Corporation (IFC) and the Financial Times entitled “A new paradigm for increased access to healthcare in Africa”.
Dr Bernhard Schwartländer currently holds the position of Director for Evidence, Innovation and Policy at UNAIDS. He took up this position in May 2010 when he joined UNAIDS at headquarters in Geneva, Switzerland, from his assignment as the United Nations Country Coordinator on AIDS in Beijing, China. Prior to these assignments, Dr Schwartländer held a number of senior international positions including: the Director for Performance Evaluation and Policy at the Global Fund to Fight AIDS, Tuberculosis and Malaria; Director of the World Health Organization's HIV Department; and as the Director of Evaluation and Strategic Information at UNAIDS.
In 2000, Dr Schwartländer undertook a special assignment to the World Bank to perform economic analyses on the cost and impact of the HIV/AIDS epidemic and the responses to it. Prior to joining the United Nations, Dr Schwartländer was the Director of the national AIDS programme in Germany and the Director of the Division of Infectious Disease Epidemiology at the Robert Koch-Institut in Berlin, the central biomedical and infectious disease research and reference laboratory of the federal Ministry of Health, Germany.
Dr Schwartländer has published widely in scientific journals and books and taught applied epidemiology in Berlin. He brings extensive experience in development policies as well as infectious disease epidemiology and programming at global and country levels.
Dr Schwartländer is a medical doctor and holds a doctorate in medical epidemiology. He received his education and professional training in Germany and the US at the Centers for Disease Control and Prevention.